Standard care for patients in this setting includes plasma exchange and immunosuppressant medicines, and trial results show that adding Cablivi reduces:
* the time it takes to bring platelet levels back to normal
* the number of plasma exchange treatments needed
* time in hospital and intensive care.
Adding Cablivi could also reduce the long-term complications of acquired TTP and risk of death around the time of an acute episode…